RGD peptide conjugation results in enhanced antitumor activity of PD0325901 against glioblastoma by both tumor-targeting delivery and combination therapy.

@article{Hou2016RGDPC,
  title={RGD peptide conjugation results in enhanced antitumor activity of PD0325901 against glioblastoma by both tumor-targeting delivery and combination therapy.},
  author={Jianjun Hou and Yiping Diao and Wei Li and Zhenjun Yang and Lihe Zhang and Zili Chen and Yun Wu},
  journal={International journal of pharmaceutics},
  year={2016},
  volume={505 1-2},
  pages={329-40}
}
Glioblastoma (GBM) is the most aggressive tumor type in the central nervous system. Both tumor-targeting drug delivery and combination therapy of multiple therapeutic agents with distinct mechanisms are important for GBM treatment. We combined these two strategies and developed a new platform of peptide-drug conjugate (RGD-PEG-Suc-PD0325901, W22) for tumor-targeting delivery using a combination of PD0325901 (a MEK1/2 inhibitor) and RGD peptide. In the present study, the combination of PD0325901… CONTINUE READING